Share price · ABVX
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when ABVX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 28 Sep 2026+6.4%
Nothing announced by ABVX that day or the session before.
- 30 Jun 2026+38.6%
- 4 Jun 2026+16.4%
Nothing announced by ABVX that day or the session before.
- 3 Jun 2026+24.3%
- 2 Jun 2026-44.1%
- 30 Apr 2026+10.5%
Nothing announced by ABVX that day or the session before.
- 13 Apr 2026-3.8%
Nothing announced by ABVX that day or the session before.
- 22 Dec 2025+20.7%
Nothing announced by ABVX that day or the session before.
- 9 Dec 2025+6.9%
Nothing announced by ABVX that day or the session before.
- 20 Nov 2025+8.8%
Nothing announced by ABVX that day or the session before.
Share of unusual movement by asset
For each asset, the share of ABVX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | miR-124Small molecule | Inflammatory Bowel Disease Ulcerative Colitis, Crohn's Disease |
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (2)
December 2026 (2)
What to watch
What to watch
2028 (1)
March 2028 (1)
What to watch
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (9)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-H1 | — | $126M | $443M+ $16M short-term inv. | $97M | report ↗ |
View 8 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q1 | — | $56M | $559M | $64M | report ↗ |
| 2025-Q3 | — | $65M | $692M+ $0 short-term inv. | $179M-$83M operating cash flow | report ↗ |
| 2025-H1 | — | $85M | $71M | $36M | report ↗ |
| 2025-Q2 | — | $44M | $71M+ $0 short-term inv. | $55M-$38M operating cash flow | report ↗ |
| 2025-Q1 | — | $41M | $112M+ $0 short-term inv. | $55M-$35M operating cash flow | report ↗ |
| 2024-Q3 | — | $48M | $202M | $61M-$39M operating cash flow | report ↗ |
| 2024-Q2 | — | $31M | $238M | $42M-$54M operating cash flow | report ↗ |
| 2024-Q1 | — | $39M | $261M | $47M-$38M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $202M | $607M+ $0 short-term inv. | $95M-$183M operating cash flow | report ↗ |
Abivax reported no revenue for 2025, with neither current nor prior-year revenue disclosed. R&D spend was $201.5M, up 27.1% YoY, cash and equivalents were $607.44M, and the company reported a net loss of $380.98M, with a quarterly net burn of $380.98M.
The company expects a cash runway into Q4 2027 and remains on track to report ABTECT-UC maintenance topline results in late Q2 2026, with Phase 2b Crohn’s disease induction results and an obefazimod NDA submission in UC both expected in Q4 2026, subject to positive data. A DSMB review on March 18, 2026 found no new safety signals, with nearly 90% of participants having completed the 44-week treatment period. Key developments included senior leadership appointments, including a new Chief Commercial Officer, and the planned AGM on May 11, 2026.
Insider transactions
This company files with the SEC but has no Section 16 insider reports. This is typical for foreign private issuers, which are exempt from Form 4 reporting.
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 251 reporting institutions held 50.3M shares ($5.4B, 57.7% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | TCG Crossover Management, LLC | 6,481,085 | $721.7M |
| 2 | UBS Group AG | 4,547,406 | $506.4M |
| 3 | Darwin Global Management, Ltd. | 3,468,657 | $352.1M |
| 4 | MORGAN STANLEY | 1,704,958 | $189.8M |
| 5 | Vestal Point Capital, LP | 1,500,000 | $167.0M |
| 6 | Caligan Partners LP | 1,461,924 | $162.8M |
| 7 | ADAR1 Capital Management, LLC | 1,394,019 | $155.2M |
| 8 | WESTFIELD CAPITAL MANAGEMENT CO LP | 1,322,938 | $147.3M |
| 9 | FMR LLC | 1,286,373 | $143.2M |
| 10 | Helikon Investments Ltd | 1,013,324 | $112.8M |
| 11 | Eversept Partners, LP | 934,423 | $104.0M |
| 12 | JANUS HENDERSON GROUP PLC | 878,829 | $98.0M |
| 13 | BAKER BROS. ADVISORS LP | 875,796 | $97.5M |
| 14 | Paradigm Biocapital Advisors LP | 772,473 | $86.0M |
| 15 | Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A. | 765,915 | $85.3M |